Effects and cost of glycyrrhizin in the treatment of upper respiratory tract infections in members of the Japanese maritime self-defense force: Preliminary report of a prospective, randomized, double-blind, controlled, parallel-group, alternate-day treatment assignment clinical trial

Yanagawa, Youichi; Ogura, Masatsune; Fujimoto, Eita; Shono, Shinjiro; Okuda, Eriya

doi:10.1016/s0011-393x(04)90002-1

Cited by 25 publications

(18 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…was even more potent to inhibit hyaluronidase activity than glycyrrhizin [292]. Glycyrrhizin has been used to treat patients with chronic hepatitis C [293] as well as upper respiratory tract infections [294]. Inhibition of hyaluronidase activity with 6-O-Palmitoyl-L-ascorbic acid (VCPAL) promoted remyelination which may benefit patients with multiple sclerosis [43].…”

Section: Ha As Therapeuticmentioning

confidence: 99%

Hyaluronan as a therapeutic target in human diseases

Liang

Jiang

Noble

2016

Advanced Drug Delivery Reviews

186

117

View full text Add to dashboard Cite

Accumulation and turnover of extracellular matrix is a hallmark of tissue injury, repair and remodeling in human diseases. Hyaluronan is a major component of the extracellular matrix and plays an important role in regulating tissue injury and repair, and controlling disease outcomes. The function of hyaluronan depends on its size, location, and interactions with binding partners. While fragmented hyaluronan stimulates the expression of an array of genes by a variety of cell types regulating inflammatory responses and tissue repair, cell surface hyaluronan provides protection against tissue damage from the environment and promotes regeneration and repair. The interactions of hyaluronan and its binding proteins participate in the pathogenesis of many human diseases. Thus, targeting hyaluronan and its interactions with cells and proteins may provide new approaches to developing therapeutics for inflammatory and fibrosing diseases. This review focuses on the role of hyaluronan in biological and pathological processes, and as a potential therapeutic target in human diseases.

show abstract

Section: Ha As Therapeuticmentioning

confidence: 99%

Hyaluronan as a therapeutic target in human diseases

Liang

Jiang

Noble

2016

Advanced Drug Delivery Reviews

186

117

View full text Add to dashboard Cite

show abstract

“…It mainly consists of dried roots and stolons of Glycyrrhizae uralensis, G. inflate and G. glabra. Licorice is prescribed with other herbal medicines as a demulcent in the treatment of sore throats, an expectorant for coughs and bronchial catarrh, an antitussive, a tastemodifying agent for relieving pain, an anti-inflammatory agent for anti-allergic reactions, rheumatism and arthritis, a prophylactic for liver disease and tuberculosis and adrenocorticoid insufficiency [23][24][25][26][27]. The phamacological properties of licorice depend upon glycyrrhizin (GC), which is con- Fig.…”

Section: A Single Step Purification Of Glyccy-rhizin By Immunoaffinitmentioning

confidence: 99%

Preparation of Knockout Extract for Determination of Really Active Compound Using MAb

Uto

Tuvshintogtokh²,

Shoyama³

2011

CDDT

View full text Add to dashboard Cite

The crude-rhizome extract of P. japonicus was loaded on the immunoaffinity column conjugated with anti- ginsenoside-Rb1 monoclonal antibody (MAb) and washed with the washing solvent, followed by elution solvent, to give fraction 2 containing higher concentration of compound 1. Compound 1 clearly indicated a dammarane saponin having protopanaxadiol as a framework and three sugars in a molecule suggesting that compound 1 is chikusetsusaponin III. Compound 2 was also determined as chikusetsusaponin VI compared to the staining color, its Rf value and the comparison with ginsenoside Rb1. We succeeded in one step purification of ginsenoside-Rb1 by immunoaffinity column conjugated with anti- ginsenoside-Rb1 MAb leading to the knock-out extract which will be useful for pharmacological investigation. The antibody was stable when exposed to the eluent, and the immunoaffinity column showed almost no decrease in capacity after repeated use more than 10 times under the same conditions. From the crude extract of licorice we isolated glycyrrhizin by one-step purification by the immunoaffinity column using anti-glycyrrhizin MAb. Washing fraction contained all components except for only glycyrrhizin and was named as the knockout extract. We confirmed the synergic effect of glycyrrhizin with some other components for the inhibition of nitric oxide (NO) production by blocking inducible nitric oxide synthase (iNOS) expression by using its knockout extract.

show abstract

“…A preparation of GL combined with l-cysteine and glycine (Stronger Neo-Minophagen C, SNMC) has been a registered in Japan and other countries. SNMC is administered intravenously, and has been used with apparent success for the treatment of chronic viral hepatitis (Miyake et al, 2002) and upper respiratory tract infections (Yanagawa et al, 2004). Haiying et al (2003) reported at the "Annual Meeting of the Society of Infectious and Parasitic Diseases, Chinese Medical Association" on the use of intravenous SNMC for the treatment of 37 SARS patients compared to 36 patients solely treated with corticosteroids.…”

Section: Glycyrrhizin and Derivativesmentioning

confidence: 99%

Development of antiviral therapy for severe acute respiratory syndrome

et al. 2005

View full text Add to dashboard Cite

A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.

show abstract

Effects and cost of glycyrrhizin in the treatment of upper respiratory tract infections in members of the Japanese maritime self-defense force: Preliminary report of a prospective, randomized, double-blind, controlled, parallel-group, alternate-day treatment assignment clinical trial

Abstract: Background:Upper respiratory tract infections (URTIs) account for at least

Cited by 25 publications

References 11 publications

Hyaluronan as a therapeutic target in human diseases

Hyaluronan as a therapeutic target in human diseases

Preparation of Knockout Extract for Determination of Really Active Compound Using MAb

Development of antiviral therapy for severe acute respiratory syndrome

Contact Info

Product

Resources

About